Lineage Cell Therapeutics Inc. — Director's Dealing 2012

Jul 3, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-07-01

Reporting Person: VON ESCHENBACH ANDREW C. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-07-01	Option to Purchase Common Shares	$4.60	A	20000	Acquired	2017-06-30	Common Shares (20000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$4.06	2016-11-27	Common Shares (20000)	20000	Direct

Footnotes

F1: 5,000 options will become exercisable on September 30, 2012; December 31, 2012; March 31, 2013; and June 30, 2013 based upon continued service on the board of directors.

F2: 5,000 options became exercisable on December 31, 2011; March 31, 2012; and June 30, 2012. The remaining 5,000 options will become exercisable on September 30, 2012 based upon continued service on the board of directors.